Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial
- Resource Type
- Article
- Authors
- Long, Georgina V; Saw, Robyn P M; Lo, Serigne; Nieweg, Omgo E; Shannon, Kerwin F; Gonzalez, Maria; Guminski, Alexander; Lee, Jenny H; Lee, Hansol; Ferguson, Peter M; Rawson, Robert V; Wilmott, James S; Thompson, John F; Kefford, Richard F; Ch'ng, Sydney; Stretch, Jonathan R; Emmett, Louise; Kapoor, Rony; Rizos, Helen; Spillane, Andrew J; Scolyer, Richard A; Menzies, Alexander M
- Source
- In The Lancet Oncology July 2019 20(7):961-971
- Subject
- Primary Research
Articles
- Language
- ISSN
- 1470-2045